Abstract
Seizures are a frequent symptom in patients with glioblastoma and bear a relevant impact on quality of life.1–3 Retrospective studies have indicated that temozolomide may improve seizure control in glioma patients.2,4 Bevacizumab, an approved treatment for recurrent glioblastoma,3 may also decrease seizure frequency, eg, by reducing edema, with potential implications for quality of life. Bevacizumab was approved in Switzerland in 2009 and epidemiological data showed that bevacizumab use increased in the Canton of Zurich in the years 2010-2014.5 Here, we retrospectively reviewed the electronic charts of glioblastoma patients at first recurrence treated either with (N = 55) or without (N = 61) a bevacizumab-containing regimen. Patients were diagnosed with glioblastoma6 between 2010 and 2014 in the Canton of Zurich and were treated at the University Hospital Zurich. Occurrences and dynamics of seizures before and after first recurrence were assessed. Categorical and continuous variables were compared by the chi-square and the Mann-Whitney U test, respectively. Associations of clinical parameters and seizures were analyzed by binary logistic regression. This study was approved by the local ethics committee (KEK-ZH-Nr. 2015-0437).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
